A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin

Jean L Grem, Mary G. Quinn, Bruce Keith, Brian P. Monahan, J. Michael Hamilton, Yan Xu, Nancy Harold, Dat Nguyen, Chris H. Takimoto, Anthony Rowedder, Janet Pang, Geraldine Morrison, Alice Chen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2′-deoxyuridine (FUDR), we studied this combination in a phase I trial. Methods: Gemcitabine alone was given in cycle 1 as a 24-h, 2-h or 1-h i.v. infusion weekly for 3 of 4 weeks; if tolerated, a 24-h i.v. infusion of FUDR was added with oral leucovorin. The cycle was aborted for grade 3 thrombocytopenia, grade 4 neutropenia, and grade 2 or worse nonhematologic toxicity. Results: During cycle 1, six of eight patients who received 150 or 100 mg/m2 over 24 h had dose-limiting neutropenia, thrombocytopenia, fatigue or mucositis. Six of seven patients treated with 1000 mg/m2 over 2 h required a gemcitabine dose reduction for cycle 2 (thrombocytopenia, neutropenia, fatigue). Of 25 assessable patients who received gemcitabine 1000 mg/m2 over 1 h, 7 did not complete cycle 1 due to thrombocytopenia (n = 6) or diarrhea (n = 1). Of 42 patients entered, 27 received at least one course of gemcitabine/FUDR (5-19.5 mg/m2 over 24 h) without appreciable toxicity. Due to a shortage of FUDR, the protocol was closed early. Gemcitabine plasma concentrations averaged 0.061 μM (24 h), 16.3 μM (2 h), and 31.9 μM (1 h). In 21 paired bone marrow mononuclear cell samples obtained before treatment and during FUDR infusion, thymidylate synthase ternary complex was only seen during FUDR infusion. Conclusions: Gemcitabine 100-150 mg/m2 over 24 h was poorly tolerated, whereas toxicity was acceptable with 800-1000 mg/m2 over 1 h. Inhibition of the target enzyme was demonstrated at all FUDR doses.

Original languageEnglish (US)
Pages (from-to)487-496
Number of pages10
JournalCancer Chemotherapy and Pharmacology
Volume52
Issue number6
DOIs
StatePublished - Dec 1 2003

Fingerprint

gemcitabine
Floxuridine
Leucovorin
Deoxyuridine
Neutropenia
Toxicity
Thrombocytopenia
Fatigue
Fatigue of materials
Thymidylate Synthase
Mucositis
Cytotoxicity
Bone Marrow Cells
DNA Damage
Diarrhea
Bone

Keywords

  • Antimetabolites
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin. / Grem, Jean L; Quinn, Mary G.; Keith, Bruce; Monahan, Brian P.; Hamilton, J. Michael; Xu, Yan; Harold, Nancy; Nguyen, Dat; Takimoto, Chris H.; Rowedder, Anthony; Pang, Janet; Morrison, Geraldine; Chen, Alice.

In: Cancer Chemotherapy and Pharmacology, Vol. 52, No. 6, 01.12.2003, p. 487-496.

Research output: Contribution to journalArticle

Grem, JL, Quinn, MG, Keith, B, Monahan, BP, Hamilton, JM, Xu, Y, Harold, N, Nguyen, D, Takimoto, CH, Rowedder, A, Pang, J, Morrison, G & Chen, A 2003, 'A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin', Cancer Chemotherapy and Pharmacology, vol. 52, no. 6, pp. 487-496. https://doi.org/10.1007/s00280-003-0698-5
Grem, Jean L ; Quinn, Mary G. ; Keith, Bruce ; Monahan, Brian P. ; Hamilton, J. Michael ; Xu, Yan ; Harold, Nancy ; Nguyen, Dat ; Takimoto, Chris H. ; Rowedder, Anthony ; Pang, Janet ; Morrison, Geraldine ; Chen, Alice. / A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin. In: Cancer Chemotherapy and Pharmacology. 2003 ; Vol. 52, No. 6. pp. 487-496.
@article{50b7155cf36e4b908e56f072167b3fd7,
title = "A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin",
abstract = "Purpose: Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2′-deoxyuridine (FUDR), we studied this combination in a phase I trial. Methods: Gemcitabine alone was given in cycle 1 as a 24-h, 2-h or 1-h i.v. infusion weekly for 3 of 4 weeks; if tolerated, a 24-h i.v. infusion of FUDR was added with oral leucovorin. The cycle was aborted for grade 3 thrombocytopenia, grade 4 neutropenia, and grade 2 or worse nonhematologic toxicity. Results: During cycle 1, six of eight patients who received 150 or 100 mg/m2 over 24 h had dose-limiting neutropenia, thrombocytopenia, fatigue or mucositis. Six of seven patients treated with 1000 mg/m2 over 2 h required a gemcitabine dose reduction for cycle 2 (thrombocytopenia, neutropenia, fatigue). Of 25 assessable patients who received gemcitabine 1000 mg/m2 over 1 h, 7 did not complete cycle 1 due to thrombocytopenia (n = 6) or diarrhea (n = 1). Of 42 patients entered, 27 received at least one course of gemcitabine/FUDR (5-19.5 mg/m2 over 24 h) without appreciable toxicity. Due to a shortage of FUDR, the protocol was closed early. Gemcitabine plasma concentrations averaged 0.061 μM (24 h), 16.3 μM (2 h), and 31.9 μM (1 h). In 21 paired bone marrow mononuclear cell samples obtained before treatment and during FUDR infusion, thymidylate synthase ternary complex was only seen during FUDR infusion. Conclusions: Gemcitabine 100-150 mg/m2 over 24 h was poorly tolerated, whereas toxicity was acceptable with 800-1000 mg/m2 over 1 h. Inhibition of the target enzyme was demonstrated at all FUDR doses.",
keywords = "Antimetabolites, Pharmacodynamics, Pharmacokinetics",
author = "Grem, {Jean L} and Quinn, {Mary G.} and Bruce Keith and Monahan, {Brian P.} and Hamilton, {J. Michael} and Yan Xu and Nancy Harold and Dat Nguyen and Takimoto, {Chris H.} and Anthony Rowedder and Janet Pang and Geraldine Morrison and Alice Chen",
year = "2003",
month = "12",
day = "1",
doi = "10.1007/s00280-003-0698-5",
language = "English (US)",
volume = "52",
pages = "487--496",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin

AU - Grem, Jean L

AU - Quinn, Mary G.

AU - Keith, Bruce

AU - Monahan, Brian P.

AU - Hamilton, J. Michael

AU - Xu, Yan

AU - Harold, Nancy

AU - Nguyen, Dat

AU - Takimoto, Chris H.

AU - Rowedder, Anthony

AU - Pang, Janet

AU - Morrison, Geraldine

AU - Chen, Alice

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Purpose: Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2′-deoxyuridine (FUDR), we studied this combination in a phase I trial. Methods: Gemcitabine alone was given in cycle 1 as a 24-h, 2-h or 1-h i.v. infusion weekly for 3 of 4 weeks; if tolerated, a 24-h i.v. infusion of FUDR was added with oral leucovorin. The cycle was aborted for grade 3 thrombocytopenia, grade 4 neutropenia, and grade 2 or worse nonhematologic toxicity. Results: During cycle 1, six of eight patients who received 150 or 100 mg/m2 over 24 h had dose-limiting neutropenia, thrombocytopenia, fatigue or mucositis. Six of seven patients treated with 1000 mg/m2 over 2 h required a gemcitabine dose reduction for cycle 2 (thrombocytopenia, neutropenia, fatigue). Of 25 assessable patients who received gemcitabine 1000 mg/m2 over 1 h, 7 did not complete cycle 1 due to thrombocytopenia (n = 6) or diarrhea (n = 1). Of 42 patients entered, 27 received at least one course of gemcitabine/FUDR (5-19.5 mg/m2 over 24 h) without appreciable toxicity. Due to a shortage of FUDR, the protocol was closed early. Gemcitabine plasma concentrations averaged 0.061 μM (24 h), 16.3 μM (2 h), and 31.9 μM (1 h). In 21 paired bone marrow mononuclear cell samples obtained before treatment and during FUDR infusion, thymidylate synthase ternary complex was only seen during FUDR infusion. Conclusions: Gemcitabine 100-150 mg/m2 over 24 h was poorly tolerated, whereas toxicity was acceptable with 800-1000 mg/m2 over 1 h. Inhibition of the target enzyme was demonstrated at all FUDR doses.

AB - Purpose: Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2′-deoxyuridine (FUDR), we studied this combination in a phase I trial. Methods: Gemcitabine alone was given in cycle 1 as a 24-h, 2-h or 1-h i.v. infusion weekly for 3 of 4 weeks; if tolerated, a 24-h i.v. infusion of FUDR was added with oral leucovorin. The cycle was aborted for grade 3 thrombocytopenia, grade 4 neutropenia, and grade 2 or worse nonhematologic toxicity. Results: During cycle 1, six of eight patients who received 150 or 100 mg/m2 over 24 h had dose-limiting neutropenia, thrombocytopenia, fatigue or mucositis. Six of seven patients treated with 1000 mg/m2 over 2 h required a gemcitabine dose reduction for cycle 2 (thrombocytopenia, neutropenia, fatigue). Of 25 assessable patients who received gemcitabine 1000 mg/m2 over 1 h, 7 did not complete cycle 1 due to thrombocytopenia (n = 6) or diarrhea (n = 1). Of 42 patients entered, 27 received at least one course of gemcitabine/FUDR (5-19.5 mg/m2 over 24 h) without appreciable toxicity. Due to a shortage of FUDR, the protocol was closed early. Gemcitabine plasma concentrations averaged 0.061 μM (24 h), 16.3 μM (2 h), and 31.9 μM (1 h). In 21 paired bone marrow mononuclear cell samples obtained before treatment and during FUDR infusion, thymidylate synthase ternary complex was only seen during FUDR infusion. Conclusions: Gemcitabine 100-150 mg/m2 over 24 h was poorly tolerated, whereas toxicity was acceptable with 800-1000 mg/m2 over 1 h. Inhibition of the target enzyme was demonstrated at all FUDR doses.

KW - Antimetabolites

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0344513359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344513359&partnerID=8YFLogxK

U2 - 10.1007/s00280-003-0698-5

DO - 10.1007/s00280-003-0698-5

M3 - Article

VL - 52

SP - 487

EP - 496

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -